Trial Profile
A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Assess the Safety and Efficacy of TD-1211 in Subjects With Opioid-Induced Constipation.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 25 Jan 2021
Price :
$35
*
At a glance
- Drugs Axelopran (Primary)
- Indications Constipation
- Focus Therapeutic Use
- Sponsors Theravance
- 21 May 2013 Results presented at the Digestive Disease Week 2013.
- 11 May 2013 Results from a prespecified week-to-week analysis presented at the 32nd Annual Scientific Meeting of the American Pain Society.
- 11 May 2013 Effects of treatment on pain and opioid dose outcomes presented at the 32nd Annual Scientific Meeting of the American Pain Society.